E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Record First Quarter 2022 Financial Results
May 05, 2022 16:00 ET | electroCore, Inc.
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ...
ODYY-Main.png
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
May 05, 2022 08:30 ET | Odyssey Group Intl Inc.
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products,...
True Lacrosse Athlete
True Lacrosse Advances Player Safety With HEADCHECK HEALTH Partnership
May 03, 2022 09:00 ET | HeadCheck Health, Inc.
CHICAGO, May 03, 2022 (GLOBE NEWSWIRE) -- True Lacrosse, LLC. ("True Lacrosse"), and HEADCHECK HEALTH, Inc. ("HEADCHECK"), a leading tech-enabled provider of concussion protocol management for...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce First Quarter 2022 Financial Results on May 5
April 28, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
April 26, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
April 21, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published...
Vice Admiral (r) Timothy Szymanski
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
April 20, 2022 08:30 ET | Odyssey Group Intl Inc.
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
April 19, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
April 12, 2022 08:00 ET | electroCore, Inc.
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
April 05, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an...